Torsten Falk, PhD

Dr. Falk has a background in molecular neurobiology, receiving his doctorate at the University of Hamburg in Germany, and in neurophysiology. For more than two decades, his research has focused on cellular and rodent models to test novel therapies for Parkinson’s disease (PD) treatment. He is the author of over 40 peer-reviewed journal publications, with an h index of 21 and an I10 index of 30 (as of October 31, 2024), and over 140 peer-reviewed abstracts and conference presentations. Dr. Falk holds two patents, and he has advanced one pharmacological treatment for LID to currently ongoing clinical trials. He is a member of the Society for Neuroscience and of the International Parkinson and Movement Disorder Society. He also is co-founder of Teleport Pharmaceuticals, LLC. Dr. Falk is on Grant Review Committees of the Parkinson’s Foundation and the National Institutes of Health (NINDS). He has also reviewed for the Michael J. Fox Foundation for Parkinson’s Research, the Parkinson’s UK Foundation, the American Parkinson’s Disease Association and the National Science Foundation.